Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers
- PMID: 1730487
- PMCID: PMC257661
- DOI: 10.1128/iai.60.2.536-541.1992
Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers
Abstract
Three attenuated Salmonella typhi strains have been constructed by introducing deletions in aroC and aroD or deletions in cya and crp into one of two wild-type parent strains, Ty2 or ISP1820. These mutant strains were designated CVD 906 (ISP1820 delta aroC delta aroD), CVD 908 (Ty2 delta aroC delta aroD), and chi 3927 (Ty2 delta cya delta crp). Two studies were conducted with 36 healthy adult inpatient volunteers to determine in a double-blind fashion the safety and immunogenicity of approximately 5 x 10(4) and 5 x 10(5) CFU of each of these three vaccine candidates given as a single dose. No statistically significant difference in the incidence of reactions among vaccinees was observed. Fever (oral temperature greater than or equal to 38.2 degrees C) occurred in 2 of 12 volunteers who received CVD 906, in 0 of 12 who received CVD 908, and in 1 of 12 who received chi 3927. Vaccine bacteremia without symptoms occurred in 1 of 12 vaccinees who received CVD 906, in 0 of 12 who received CVD 908, and in 2 of 12 who received chi 3927. Overall, 19 (53%) of 36 vaccinees developed immunoglobulin G antibody to S. typhi lipopolysaccharide after vaccination, with no statistically significant differences in the rate of seroconversion among volunteers in the three groups. We conclude that defined mutations in the aromatic biosynthetic pathway and in the cyclic AMP global regulatory system attenuate S. typhi. Mutant strains CVD 906, CVD 908, and chi 3927 are highly (and approximately equally) immunogenic but possibly differ in their propensity to induce fever. Further studies are needed to document the apparent relative safety of CVD 908 as a typhoid vaccine and as a vaccine carrier of foreign antigens.
Similar articles
-
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.Vaccine. 1992;10(7):443-6. doi: 10.1016/0264-410x(92)90392-w. Vaccine. 1992. PMID: 1609547 Clinical Trial.
-
Concomitant induction of CD4+ and CD8+ T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA.J Immunol. 2003 Mar 1;170(5):2734-41. doi: 10.4049/jimmunol.170.5.2734. J Immunol. 2003. PMID: 12594304 Clinical Trial.
-
Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.Vaccine. 2006 Jan 12;24(2):116-23. doi: 10.1016/j.vaccine.2005.08.008. Epub 2005 Aug 18. Vaccine. 2006. PMID: 16140433 Clinical Trial.
-
CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression.Clin Infect Dis. 2007 Jul 15;45 Suppl 1:S20-3. doi: 10.1086/518135. Clin Infect Dis. 2007. PMID: 17582563 Review.
-
Clinical and field trials with attenuated Salmonella typhi as live oral vaccines and as "carrier" vaccines.Res Microbiol. 1990 Sep-Oct;141(7-8):807-16. doi: 10.1016/0923-2508(90)90114-6. Res Microbiol. 1990. PMID: 2101470 Review.
Cited by
-
Salmonella enterica serovar Typhi live vector vaccines finally come of age.Immunol Cell Biol. 2009 Jul;87(5):400-12. doi: 10.1038/icb.2009.31. Epub 2009 May 5. Immunol Cell Biol. 2009. PMID: 19417771 Free PMC article. Review.
-
Transepithelial signaling to neutrophils by salmonellae: a novel virulence mechanism for gastroenteritis.Infect Immun. 1995 Jun;63(6):2302-9. doi: 10.1128/iai.63.6.2302-2309.1995. Infect Immun. 1995. PMID: 7768613 Free PMC article.
-
Vaccination Method Affects Immune Response and Bacterial Growth but Not Protection in the Salmonella Typhimurium Animal Model of Typhoid.PLoS One. 2015 Oct 28;10(10):e0141356. doi: 10.1371/journal.pone.0141356. eCollection 2015. PLoS One. 2015. PMID: 26509599 Free PMC article.
-
Vaccines for preventing typhoid fever.Cochrane Database Syst Rev. 2018 May 31;5(5):CD001261. doi: 10.1002/14651858.CD001261.pub4. Cochrane Database Syst Rev. 2018. PMID: 29851031 Free PMC article.
-
New technologies in developing recombinant attenuated Salmonella vaccine vectors.Microb Pathog. 2013 May;58:17-28. doi: 10.1016/j.micpath.2012.10.006. Epub 2012 Nov 8. Microb Pathog. 2013. PMID: 23142647 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous